古汉医药集团股份公司 关于控股子公司重大诉讼的公告

Core Viewpoint - The company, Hunan Qidi Pharmaceutical Bio Co., Ltd., a subsidiary of Guhang Pharmaceutical Group, has initiated a lawsuit against Ningbo Yiduoduo E-commerce Co., Ltd. for the return of contract funds amounting to RMB 20 million due to non-delivery of goods as per the sales contract [3][4]. Group 1: Lawsuit Details - The lawsuit is currently in the first-instance court, with the case number (2026) Jing 0108 Min Chu 2924, and it has not yet been scheduled for a hearing [2]. - The total amount involved in the lawsuit includes the contract amount of RMB 20 million, along with claims for capital occupation losses, legal fees, preservation fees, and litigation costs [3][4]. - The plaintiff, Hunan Qidi Pharmaceutical Bio Co., Ltd., has fully paid the contract amount of RMB 23.292 million but has not received the goods as agreed [4]. Group 2: Legal Claims - The company requests the court to order the defendant to return the contract amount of RMB 20 million and to compensate for capital occupation losses, including breach of contract responsibilities [5]. - The company also seeks to hold the other two defendants, Fuzhou Letuo Enterprise Management Co., Ltd. and Beijing Tuduo E-commerce Co., Ltd., jointly liable for the obligations of the first defendant [6]. - The lawsuit includes a request for the defendants to cover all associated costs, including preservation fees and litigation fees [8]. Group 3: Financial Impact - The company has recognized the potential financial impact of the lawsuit and has fully provisioned for bad debts related to the receivables involved in this lawsuit for the fiscal year 2024 [8]. - The outcome of the lawsuit remains uncertain, and the company cannot currently determine the effect on its current or future profits [8].